Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision

Krystal Biotech, Inc. (NASDAQ:KRYS) is one of the 10 best NASDAQ growth stocks to buy for the next 10 years. Andrea Tan, an analyst at Goldman Sachs, raised the firm’s price target on Krystal Biotech, Inc. (NASDAQ:KRYS) from $206 to $327 on January 30 while keeping a Buy rating. The firm’s revised price target implies an additional 16.7% upside from current levels. The company is positioning itself for short-term growth through three registrational programs. These programs include KB801, KB803, and KB407. All three programs are expected to support potential product launches around 2028, as outlined in a research note to investors.

The firm sees Ophthalmic programs as de-risked. They are also considered highly scalable because they can build on the existing Vyjuvek commercial platform. KB407 is also viewed as a promising opportunity in cystic fibrosis. However, stronger confidence in its long-term potential will depend on additional FEV1 data.

Moreover, on January 26, Clear Street analyst William Maughan increased the firm’s price target on Krystal Biotech, Inc. (NASDAQ:KRYS) from $288 to $338 while maintaining a Buy rating. The upward-adjusted price target offers a further 20.7% upside from the current levels. According to the analyst, the recent share price strength has been supported by the continued growth of Vyjuvek. It also pointed to the growing investor appreciation for the company’s expanding pipeline.

The firm also noted that the most sustained source of investor excitement is focused on the company’s potential in the neurotrophic keratitis market, driven by KB801. The higher estimates of KB801 were a key factor behind the upward revision in its price target, according to the firm.

In addition to Clear Street, Bank of America also raised its price target on Krystal Biotech, Inc. (NASDAQ:KRYS) from $288 to $318 on January 22 while keeping a Buy rating. The firm’s revised price target implies an additional 13.8% upside from current levels. The firm highlighted continued growth in Vyjuvek as a key support for the story. Beyond that, the analyst said that investors are expected to pay close attention to the timing of upcoming neurotrophic keratitis (NK) data as BofA views it as a significant catalyst for the stock this year.

Krystal Biotech, Inc. (NASDAQ:KRYS) is a commercial-stage biotechnology company. The company develops, discovers, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs across the United States. Its products include VYJUVEK, KB105, KB104, KB407, KB707, and others. Krystal Biotech, Inc. was incorporated in 2016 and is based in Pittsburgh, Pennsylvania.

While we acknowledge the potential of KRYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT:  Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.

Disclosure: None. This article is originally published at Insider Monkey.